Julia P. Gregory received her M.B.A. from The Wharton School of The University of Pennsylvania and her B.A. in International Affairs with a minor in International Economics from George Washington University's Elliott School of International Affairs where she was elected to Phi Beta Kappa. She is currently Chairman and CEO of Isometry Advisors, Inc., a biotechnology financial and management advisory firm, has 16 years of biotechnology executive management experience and 20 years of investment banking experience. As an executive, she successfully raised more than $1.5 billion for her companies through initial public offerings, public and private offerings and creative strategic alliances with GlaxoSmithKline, BristolMyers Squibb, Takeda Pharmaceuticals, Genentech, (Roche) and Human Genome Sciences (GSK), among others. Recently, she was CEO of ContraFect Corporation, which focused on new biologics as an alternative to antibiotics. Prior to ContraFect, she was CEO of FivePrime Therapeutics, where she led a clinical-stage, biotechnology company discovering and developing innovative protein and antibody therapeutics in oncology and immunology; and was EVP, Head of Corporate Development and CFO of Lexicon Pharmaceuticals which identified the function of 5,000 genes, resulting in more than 100 protein targets with therapeutic potential in a range of diseases and a recently commercialized drug for carcinoid syndrome diarrhea. She is currently on the board of directors of Iconic Therapeutics and is an Advisor Partner to the Morgan Stanley Expansion Capital Fund.